Compare Ascendis Pharma A/S (ASND) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Ascendis Pharma A/S trades at $263.72 (market cap $17.74B), while iShares 1 3 Year Treasury Bond ETF trades at $81.83. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ASND | SHY | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Fixed Income |
52-Week High | $277.18 | $83.18 |
52-Week Low | $163.32 | $81.84 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SHY trades at $81.88, down 0.04% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators and uniform support/resistance at $82. Recent corporate actions include scheduled dividends of $0.24 per share through mid-2026, providing income stability amid flat price movement.
Outlook remains cautious due to technical bearishness and interest rate sensitivity. Opportunities include consistent dividend yields, while risks involve Federal Reserve policy shifts impacting bond ETFs. Investors should weigh income benefits against potential rate hike volatility in the fixed income sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
